Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	49.01	24.58	3.21
Research & Development	167.87	68.42	30.31
Operating Expenses	216.87	93	33.52
Operating Income	-216.87	-93	-33.52
Interest & Investment Income	34.74	9.02	0.1
Other Non Operating Income (Expenses)	-	-	-9.98
Pretax Income	-182.13	-83.99	-43.4
Income Tax Expense	0.02	-	-
Net Income	-182.15	-83.99	-43.4
Net Income to Common	-182.15	-83.99	-43.4
Shares Outstanding (Basic)	55	25	2
Shares Outstanding (Diluted)	55	25	2
Shares Change (YoY)	120.72%	915.57%	-
EPS (Basic)	-3.30	-3.36	-17.63
EPS (Diluted)	-3.30	-3.36	-17.63
Free Cash Flow	-172.33	-74.93	-17.92
Free Cash Flow Per Share	-3.12	-3.00	-7.28
EBITDA	-216.68	-	-
D&A For EBITDA	0.19	-	-
EBIT	-216.87	-93	-33.52

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q